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Up to 80% of the calcium-binding protein BM-40 could be extracted from a tumor basement membrane 
with a physiological buffer containing 10 mM EDTA. About half of its amino acid sequence was determined 
by Edman degradation demonstrating identity with cDNA deduced sequences of bone osteonectin and 
SPARC. 
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1. INTRODUCTION 
Basement membranes are unique extracellular 
protein matrices with a broad tissue distribution. 
They are composed of coUagenous protein, several 
proteoglycans and a diverse group of other 
glycoproteins which are still incompletely 
characterized [1]. Among the latter components i
also a small protein BM-40 which has recently been 
purified from 6 M guanidine-HCl extracts of the 
mouse Engelbreth-Holm-Swarm (EHS) tumor [2]. 
The protein consists of a single, disulfide-bonded 
polypeptide chain which is partially cleaved by en- 
dogenous proteases during purification. Im- 
munological assays failed to show any relationship 
to other known basement membrane proteins and 
demonstrated the widespread occurrence of BM-40 
in cell cultures and tissue extracts. It was also pre- 
sent in authentic basement membranes such as lens 
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capsule and Reichert's membrane. During the 
characterization f BM-40 [2] we noticed a possi- 
ble relationship to a serum albumin-binding pro- 
tein obtained from endothelial and other cell 
cultures [3,4] which was later named SPARC and 
characterized by a complete amino acid sequence 
deduced from murine cDNA clones [5]. An almost 
identical sequence was recently determined for 
bovine bone osteonectin (M. Bolander, personal 
communication) which is known as a calcium- 
binding protein [6,7]. 
The data suggested that calcium-binding pro- 
teins are present in basement membranes and con- 
tribute to their special architecture. Evidence for 
this possibility came initially from the findings that 
laminin polymerizes in the presence of calcium [8] 
and that extracts of the EHS tumor obtained with 
10 mM EDTA in physiological buffer contain 
large amounts of the laminin-nidogen complex [9]. 
In the present study we have applied the same ex- 
traction procedure for the purification of BM-40 in 
a more gentle manner than done before. Partial 
amino acid sequence analysis provided strong 
evidence that BM-40 is identical with SPARC and 
osteonectin. 
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2. MATERIALS AND METHODS 
Aliquots (75 g) of EHS tumor were briefly 
homogenized in 1.5 and 0.8 1 of 0.15 M NaCI, 
0.05 M Tris-HCl, pH 7.4, containing 2 mM 
phenylmethanesulfonyl fluoride (PMSF) and 
2 mM N-ethylmaleimide (NEM) as protease in- 
hibitors (TBS) and centrifuged. The remaining 
residue was extracted twice with 375 ml TBS sup- 
plemented with 10 mM EDTA by stirring for 1 h 
at 4°C [9]. Subsequent extracts were obtained with 
200 ml of 2 M and 6 M guanidine. HCI containing 
protease inhibitors (each for 1 day, 4°C). Aliquots 
(100 ml) of the first TBS-EDTA extract were 
passed over a Sepharose CI-6B column (3.2 x 
134 cm) equilibrated in TBS with 2 mM EDTA, 
0.5 mM PMSF and 0.5 mM NEM. Fractions con- 
taining BM-40 were pooled from four runs, con- 
centrated to 200 ml over an Amicon PM10 filter 
and dialyzed for 1 day at 4°C against 2 × 4 1 of 
2 M urea, 0.05 M Tris-HC1, pH 8.6, containing 
protease inhibitors. They were then passed over a 
DEAE-cellulose column (2 x 20 cm) equilibrated 
in the same solvent and bound protein was eluted 
with a linear NaCI gradient (0-0.4 M NaCI, 
800-1000 ml). Final purification of BM-40 was 
achieved on a Sephacryl S-200 column (1.5 × 
105 cm) equilibrated in 0.2 M ammonium bicar- 
bonate. 
In an alternative procedure 360 ml of the TBS- 
EDTA extract were mixed with 120 ml of 8 M urea 
and passed over a DEAE-cellulose column (3 x 
25 cm) equilibrated in the same mixture of solvents 
followed by elution with a linear gradient (total 
1000 ml) up to 0.6 M NaCI dissolved in the buffer. 
Further purification steps included chromatogra- 
phy on Sephacryl S-200 and DEAE-cellulose at pH 
8.6 as described above. In addition, BM-40 was 
purified from 6 M guanidine.HCl extracts as 
described [2]. 
Cleavage of BM-40 dissolved in 0.15 M NaCI, 
0.05 M Tris-HCl, pH 7.4, 2 mM CaCI2 by SV8 
protease was performed at an enzyme-substrate 
ratio of 1:100 for 24 h at 37°C. Other samples 
were reduced with 2 mM dithioerythritol in 0.1 M 
Tris-HCl, pH 8.5, 6 M guanidine-HC1, S- 
carboxymethylated and cleaved in 0.2 M am- 
monium bicarbonate with TPCK-trypsin (24 h, 
37°C). Peptides were separated on a Sephadex 
G75sf column (1.5 x 120 cm) in 0.2 M ammonium 
bicarbonate and/or by HPLC on a reversed-phase 
RP 318 column (Biorad, Munich) equilibrated in 
0.107o trifluoroacetic acid and eluted with 
acetonitrile gradients. 
Proteins and fragments were characterized by 
SDS-polyacrylamide gel electrophoresis [20] in 
5-15070 gradient slab gels and after hydrolysis with 
6 M HCI (24 h, 110°C) by amino acid analysis on 
a Biotronik LC 5001 analyzer. Quantitative deter- 
minations of BM-40 were carried out by the 
radioimmuno-inhibition assay [2]. Edman degra- 
dation of samples (0.1-1 nmol) was performed in 
a gas-phase (model 470A, Applied Biosystems) or 
a spinning-cup liquid-phase sequencer (model 
890 C, Beckman). Released amino acid derivatives 
were identified and quantitated by HPLC follow- 
ing the manufacturer's recommendation r by us- 
ing an isocratic HPLC system [11]. 
3. RESULTS 
We have recently developed a fast and gentle ex- 
traction protocol for the EHS tumor basement 
membrane matrix which allowed the purification 
of large quantities of the laminin-nidogen complex 
[9]. The same extracts when examined by radioim- 
munoassay contained also substantial amounts of 
BM-40 (table 1). Brief homogenization of the 
tumor in TBS releases about 20°70 of this protein 
while about 8007o is solubilized by subsequent ex- 
Table 1 
Solubilization of BM-40 by sequential extraction of the 
EHS tumor 
Extract Amount of 
BM-40 
1. 0.05 M Tris-HC1, pH 7.4, 0.15 M 
NaCI (TBS) 107 ___ 34 
2. TBS 30 + 12 
3. TBS, 10 mM EDTA 352 + 93 
4. TBS, 10 mM EDTA 31 _+ 27 
5. 2 M guanidine. HC1 5 _+ 2 
6. 6 M guanidine-HCI 9 + 6 
Sum 534 + 108 
Yields (/zg/g wet tumor) were determined by 
radioimmunoassay nd are given as average values 
(+_ SD) of 4 experiments 
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Fig.1. Initial chromatographic steps in the purification 
of BM-40 from TBS-EDTA extracts of the EHS tumor. 
(a) Passage of 100 ml extract over Sepharose C1-6B 
column (3.2 x 134 cm); (b) chromatography of four 
BM-40 pools after step a on DEAE-cellulose in 2 M 
urea, 0.05 M Tris-HC1, pH 8.6, and elution with a 
gradient from 0-0.4 M NaCI (1 1); (c) chromatography 
of 360 ml TBS-EDTA extract on DEAE-cellulose in 2 M 
urea, 0.11 M NaCI, 0.038 M Tris-HC1, pH 7.4, followed 
by a 1 1 gradient up to 0.6 M NaCI. Runs were 
monitored for absorbance at280 nm( ) and BM-40 
content (o---o) measured in aliquots of individual 
fractions by radioimmunoassay. Horizontal bars denote 
pools containing laminin-nidogen complex (LN), BM-40 
and heparan sulfate proteoglycan (PG). Arrows indicate 
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Fig.2. Comparison of BM-40 purified from TBS-EDTA 
extracts (lane 1) and from 6 M guanidine-HCI extracts 
(lane 2) and a SV8 protease digest (lane 3) by SDS- 
polyacrylamide gel electrophoresis. Samples were 
analyzed non-reduced ( - )  or after reduction with 
2-mercaptoethanol (+). Numbers on each site indicate 
the migration position of globular marker proteins 
(Mr x 10-3). 
traction with TBS containing 10 mM EDTA. Fur- 
ther extractions with concentrated guanidine. HC1 
solutions as have been used before in the purifica- 
tion of BM-40 [2] released only insignificant 
amounts of the protein (table 1). The total yield of 
BM-40 solubilized by the new extraction scheme 
was about 2-fold higher than those reported in [2]. 
The TBS-EDTA extracts were the most conve- 
nient source for the purification of BM-40 and 
contained BM-40 in a 4-fold molar excess com- 
pared to laminin-nidogen (table 1 [9]). Both com- 
ponents could be easily separated from each other 
by molecular sieve chromatography on agarose 
(fig.la). Further purification of BM-40 was 
achieved by chromatography on DEAE-cellulose 
(fig. lb) followed by a final step on Sephacryl S-200 
(not shown). The protein showed a major band in 
electrophoresis identical in mobility to BM-40 ob- 
tained by the previous procedure (fig.2) 
Table 2 
Comparison of the amino acid composition of BM-40 
with that of SPARC deduced from cDNA sequence [5] 
BM-40 SPARC 
(residues/peptide) 
Aspartic acid 34.0 33 a 
Threonine 17.2 17 
Serine 9.6 7 
Glutamic acid 47.6 46 b 
Proline 16.4 17 
Glycine 16.8 15 
Alanine 15.1 14 
Half cysteine 11. Ic 14 
Valine 18.9 20 
Methionine 2.3 5 
Isoleucine 11.0 12 
Leucine 23.9 24 
Tyrosine 6.7 7 
Phenylalanine 12.5 12 
Histidine 12.2 12 
Lysine 18.3 19 
Arginine 8.4 8 
Tryptophan n.d. 3 
Sum 282.0 285 
a Plus asparagine 
b Plus glutamine 
c Determined as S-carboxymethyl c steine 
n.d., not determined 
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demonstrating a purity of > 95°7o. An alternative 
purification procedure was based on initial 
chromatography of TBS-EDTA extracts on 
DEAE-cellulose which also separated BM-40 from 
the laminin-nidogen complex and from pro- 
teoglycans (fig.lc) and allowed the processing of 
larger amounts of material. The final products ob- 
tained by both procedures were of equivalent puri- 
ty and were obtained in yields of 2-3  mg BM-40 
from 100 g wet tumor tissue. 
The amino acid composition of BM-40 obtained 
from TBS-EDTA extracts (table 2) was com- 
parable to that reported before for BM-40 obtain- 
ed by extraction with 6 M guanidine. HCI [2]. A 
remarkable difference was observed in the extent 
of polypeptide cleavage due to endogenous pro- 
teolysis which results in two disulfide-linked 
fragments comprising about 75 and 25% of the 
mass of BM-40, respectively. This cleavage was 
nearly complete for guanidine-extracted but only 
in the order of 20-30°7o for the EDTA-extracted 
protein (fig.2). In circular dichroism studies, the 
latter material showed about 30°70 o~-helix which 
was reduced considerably after treatment with 
guanidine (Engel, J., personal communication). 
Together the data demonstrate that extraction of 
BM-40 with TBS-10 mM EDTA results in a more 
intact form of the protein than obtained 
previously. 
Purified BM-40 corresponds with a few excep- 
tions (Ser, Cys, Met) in its amino acid composi- 
tion, within the limits of analytical error (__ 10o70), 
to the composition predicted for SPARC (table 2) 
from eDNA sequences [5]. Determination of 53o/o 
of the sequence of BM-40 by Edman degradation 
(table 3) revealed so far no difference from 
SPARC confirming the very likely identity of both 
proteins. The major N-terminal sequence of 
BM-40 (APQQ) was also identical to that reported 
for bovine osteonectin [7,12]. A minor N-terminal 
sequence apparently corresponds to the en- 
dogenous cleavage site (fig.2) and located this site 
at a Leu-Leu bond in position 197/198 of SPARC. 
Further sequence data were obtained from pro- 
teolytic fragments of BM-40 primarily generated 
by cleaving the non-reduced protein with SV8 pro- 
tease. This digestion produced a large, disulfide- 
bonded fragment SPI with about half the mass of 
BM-40 (fig.2) which could be separated from 
smaller peptides on Sephadex G75sf. This frag- 
ment contained two new major N-terminal se- 
quences demonstrating the presence of two 
disulfide-linked chain fragments and in addition a 
minor sequence due to a partial cleavage within the 
Table 3 
Partial amino acid sequences of BM-40 
Component a Sequence Position in 
SPARC b 
BM-40 a: APQQTEV AEE I  VEEETVVEE 1- 20 
b: LAXDFEK NYNMYI  FPVHWQF 198-217 
Fragment SPI a: VVADNPX QNHH 48- 58 
b: LAP  LRAP L I PME 234-245 
m:GTKKGHK(L)HL  D Y 116-127 
Fragment SP2 a: TCDLDND KY I  ALE  254-266 
b: WAGCFGI  K E 268-276 
Fragment SP3 QHPI  DGY L S HTE 222-233 
Fragment SP4 QDI  NKDL V I 277-285 
Fragment SP5 KQKLRVK K I HE 173-183 
Fragment T6 LHLDYI  G P CK 123-132 
FragmentT7 YI  APCLD S ELTEFPLR 133-148 
Fragment T8 D WL K 151-154 
a Sequences of components with several chain fragments are classified as major (a,b) or minor (m, 
20-30% of a,b) sequences according to the yields of PTH derivatives. Assignment of positions 
in cases of two major sequences was done according to the known SPARC sequence [5] 
b Numbering according to [5] without signal peptide (total 285 amino acid residues) 
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larger chain. Another fragment SP2 also consisted 
of two chain fragments which are apparently con- 
nected by the last two cysteine residues found in 
the SPARC sequence [5]. All those cleavage sites 
are preceded in the SPARC sequence by a Glu 
residue [5] as expected from the specificity of the 
protease [13]. Several more sequences were deter- 
mined for some smaller peptides obtained by 
cleavage with SV8 protease (including the C- 
terminal peptide SP4) and by cleavage of reduced 
BM-40 with trypsin (table 3). 
4. DISCUSSION 
The data so far leave no doubts that mouse 
BM-40, mouse SPARC [5] and bovine osteonectin 
(Bolander, M., personal communication) are prod- 
ucts of the same gene or at least very similar genes. 
The osteonectin sequence shows 92°7o homology to 
SPARC with substantial differences in the first 20 
amino acid residues and an additional Cys residue 
located between position 191/192 of SPARC. Both 
sequences are, however, similar in domain struc- 
ture starting with a region of rather acidic nature 
( -50 residues), followed by a disulfide-bonded do- 
main (11 Cys; -90  residues), a Cys-free region 
(-100 residues) and a second disulfide-bonded 
region (3 Cys; -40  residues). Our sequence data on 
BM-40 fragments are compatible with a covalent 
connection between both disulfide-bonded o- 
mains as predicted from the presence of 14 Cys 
residues in SPARC [5]. This indicates that frag- 
ment SP 1 of BM-40 contains two segments encom- 
passing positions 48-140 and 234-253, 
respectively. The last two cysteine residues form, 
however, a separate loop as shown by sequence 
analysis of peptide SP2. How the extra cysteine 
residue found in bovine osteonectin can be accom- 
modated in this arrangement remains at the mo- 
ment an open question. 
The rather selective xtraction of BM-40 with 
physiological buffer containing EDTA suggests 
that calcium-binding changes its affinity for other 
components within the tumor basement mem- 
brane. It is in this context noteworthy that the 
same extraction procedure also solubilizes ubstan- 
tial amounts of laminin and nidogen [9] indicating 
the possible xistence of complexes between BM-40 
and these proteins. A distinct loss of re-helical 
structures has been observed after removal of 
calcium from BM-40 (Engel, J., personal com- 
munication) which could be a factor in changing 
the interaction potential for other matrix com- 
ponents. 
BM-40 has not only been detected as a compo- 
nent of the EHS tumor but is also present in lens 
capsule, Reichert's membrane and various other 
tissue extracts and cell cultures [2]. This agrees 
with similar observations on the widespread 
distribution of SPARC mRNA [14] and the fre- 
quent finding that osteonectin s produced not only 
by bone but also by several other cells [13,15-17]. 
The data demonstrate that this unique calcium- 
binding protein identified as osteonectin, SPARC 
or BM-40 is in fact a frequent constituent of 
mineralizing and non-mineralizing connective 
tissues and of basement membranes suggesting a
rather general biological role. It is likely that some 
of its functions are related to calcium-binding 
which still remain to be established. 
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